Tags

Type your tag names separated by a space and hit enter

Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.
Annu Rev Med. 1994; 45:189-200.AR

Abstract

Hypercalcemia is the most common metabolic complication of cancer. Malignancy-associated hypercalcemia (MAHC) can be divided into two syndromes, humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH), based on whether a circulating hormone or local paracrine factors mediate accelerated bone resorption. Over the past decade, studies have shown that parathyroid hormone-related protein is the cause of the HHM syndrome, and recent data suggest that this protein may also play a paracrine role in some patients with local osteolytic hypercalcemia. Study of the regulation of parathyroid hormone-related protein gene expression is beginning to shed some light on the molecular mechanisms responsible for this common clinical problem.

Links

Publisher Full Text

Authors+Show Affiliations

Wysolmerski JJ
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
Broadus AE
No affiliation info available

MeSH

Bone ResorptionGene Expression Regulation, NeoplasticHumansHypercalcemiaNeoplasm ProteinsNeoplasmsOsteolysisParaneoplastic SyndromesParathyroid HormoneParathyroid Hormone-Related ProteinProteins

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8198376

Citation

Wysolmerski, J J., and A E. Broadus. "Hypercalcemia of Malignancy: the Central Role of Parathyroid Hormone-related Protein." Annual Review of Medicine, vol. 45, 1994, pp. 189-200.
Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med. 1994;45:189-200.
Wysolmerski, J. J., & Broadus, A. E. (1994). Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annual Review of Medicine, 45, 189-200.
Wysolmerski JJ, Broadus AE. Hypercalcemia of Malignancy: the Central Role of Parathyroid Hormone-related Protein. Annu Rev Med. 1994;45:189-200. PubMed PMID: 8198376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. AU - Wysolmerski,J J, AU - Broadus,A E, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - 189 EP - 200 JF - Annual review of medicine JO - Annu Rev Med VL - 45 N2 - Hypercalcemia is the most common metabolic complication of cancer. Malignancy-associated hypercalcemia (MAHC) can be divided into two syndromes, humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH), based on whether a circulating hormone or local paracrine factors mediate accelerated bone resorption. Over the past decade, studies have shown that parathyroid hormone-related protein is the cause of the HHM syndrome, and recent data suggest that this protein may also play a paracrine role in some patients with local osteolytic hypercalcemia. Study of the regulation of parathyroid hormone-related protein gene expression is beginning to shed some light on the molecular mechanisms responsible for this common clinical problem. SN - 0066-4219 UR - https://www.unboundmedicine.com/medline/citation/8198376/Hypercalcemia_of_malignancy:_the_central_role_of_parathyroid_hormone_related_protein_ L2 - https://arjournals.annualreviews.org/doi/10.1146/annurev.med.45.1.189?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -